TCRX
HealthcareTScan Therapeutics, Inc.
$1.04
+$0.02 (+1.96%)
Jan 5, 2026
Price History (1Y)
Analysis
TScan Therapeutics, Inc. is a healthcare company operating in the biotechnology industry with a market capitalization of $59.02 million. The company has a significant scale, employing 146 individuals. Its revenue over the trailing twelve months (TTM) stands at $8.42 million. The financial health of TScan Therapeutics indicates substantial losses. Margins are negative across all categories: gross margin is -148.9%, operating margin is -1475.6%, and profit margin is 0.0%. Returns on equity and assets are also negative, at -76.4% and -30.5%, respectively. The company's balance sheet shows a substantial amount of debt ($95.62 million) but also significant cash reserves ($184.45 million), resulting in a debt-to-equity ratio of 66.39. TScan Therapeutics' valuation metrics are notable, particularly the forward P/E ratio at -1.04 and the price to sales ratio at 7.01. Revenue growth over the past year is substantial, reaching 139.4%. However, earnings growth is not available for comparison.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $59.02M
- P/E Ratio
- N/A
- 52-Week High
- $3.07
- 52-Week Low
- $0.88
- Avg Volume
- 818.55K
- Beta
- 1.04
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 146